Neurocrine Biosciences, Inc. NBIX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 206.50M | 144.40M | 197.90M | 153.70M | 209.50M |
| Total Depreciation and Amortization | 44.00M | 24.80M | 7.30M | 7.50M | 7.70M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 124.80M | 47.30M | -56.40M | 108.00M | 195.50M |
| Change in Net Operating Assets | 19.90M | -80.10M | -3.00M | 119.20M | -185.20M |
| Cash from Operations | 395.20M | 136.40M | 145.80M | 388.40M | 227.50M |
| Capital Expenditure | -11.60M | -7.80M | -9.10M | 2.40M | -13.20M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 0.00 | -2.36B | -- | -- | -- |
| Divestitures | 0.00 | 0.00 | 63.20M | -- | -- |
| Other Investing Activities | 500.00K | 2.23B | -560.30M | -55.30M | -183.50M |
| Cash from Investing | -11.10M | -135.40M | -506.20M | -52.90M | -196.70M |
| Total Debt Issued | 0.00 | 600.00M | -- | -- | -- |
| Total Debt Repaid | 0.00 | -600.00M | -- | -- | -- |
| Issuance of Common Stock | 25.30M | 84.80M | 23.60M | 37.30M | 45.60M |
| Repurchase of Common Stock | -100.30M | -14.70M | -109.70M | 0.00 | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -6.70M | -- | -- | -- |
| Cash from Financing | -75.00M | 63.40M | -86.10M | 37.30M | 45.60M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -200.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 309.10M | 64.40M | -446.50M | 372.80M | 76.20M |